U.S., Pharmaceutical Companies Should Work With, Not Against, Indian Drug Industry

SciDev.Net: Focus on Private Sector: India’s generic drug wars
Maha Rafi Atal, PhD candidate at the University of Cambridge

“…Indian companies provide cheap generic drugs to countries across the world and account for 80 percent of donor-funded HIV treatment — a set-up now threatened by U.S. pressure [to introduce ‘data exclusivity,’ which could restrict generic versions of off-patent drugs]. But Big Pharma should work with Indian companies and could even benefit by doing so. … It is crucial the Indian drug industry isn’t crippled by extreme patent reforms. The country should remind the U.S. that, as India’s generics are largely sold in poor countries, the trade will hardly damage major U.S. pharmaceutical firms in the core markets of North America, Europe, and Japan. And there might actually be lucrative partnership opportunities within this generic drug trade, with Indian firms offering expertise about trading in Africa in exchange for Western research and development resources” (8/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.